Description
Memorial Sloan Kettering Cancer Center Fundamentals and Advances in Immunotherapy in the Oncology Patient 2023
- Include: 22 videos + 18 pdfs, size: 4.5 GB
- Â Target Audience: physicians who care for oncology patients
- Sample video: contact me for sample video
 Information:
Tuesday, January 24, 2023, 7:50 AM – 5:00 PM, Online, New York , NY
Immunotherapeutics has changed the treatment modalities available to cancer patients in both solid tumors and hematologic malignancies. Since the breakthrough of ipilimumab, there have been fast-paced and ongoing advancements in the field of immunotherapy, revolutionizing clinical management rapidly.
This one-day live virtual course aims to improve cancer patient outcomes by advancing the science, development, and application of cancer immunology and immunotherapy through fundamental understanding and clinical application. Learners will review fundamental concepts and recent advances in immunotherapy designed to meet the learning needs of advanced practice providers (APPs) and other allied health professionals.
Clinical application in solid tumor and hematologic malignancies will be discussed as well as toxicity management, including immune-related adverse events resulting from immune checkpoint inhibition. Experts will discuss the fundamentals of immune checkpoint blockade and CAR T cell therapy, as well as advancements in TIL and BITE therapy, novel combination therapy, and algorithmic management of immune-related adverse events. Toxicity management will be communicated through case study applications and demonstration of common, rare, and severe immune-related adverse events.
Who Should Attend
The target audience for this course includes nurse practitioners, physician assistants, certified registered nurse anesthetists, physicians, and nurses who care for oncology patients. We are pleased to offer complimentary registration for residents, fellows, APP students, and nursing students.
- Describe the principles surrounding the immunity cycle
- Explain fundamental principles of immunotherapeutic agents including immune checkpoint inhibition, CAR T CELL , TIL, and BITE therapies.
- Discuss clinical application of immune modulated agents in the oncology population
- Discuss the symptoms of Cytokine release Syndrome and clinical management
- Recognize and identify common, rare and severe immune related adverse events attributed to immune checkpoint inhibition
 Topics:
- Algorithmic Management and Grading of Immune-Related Adverse Events.mp4
- Algorithmic Management and Grading of Immune-Related Adverse Events.pdf
- APPImmunotherapy_2023_Brochure.pdf
- BITE and CAR T cell therapy in the Acute Leukemia Patient- A Case Study Approach.mp4
- BITE and CAR T cell therapy in the Acute Leukemia Patient- A Case Study Approach.pdf
- Cardiac Immune-Related Adverse Event- Myocarditis.mp4
- Cardiac Immune-Related Adverse Event- Myocarditis.pdf
- Clinical Application of Immune Checkpoint Inhibitors in Solid Tumor Malignancy Panel Discussion.mp4
- Clinical Application of Immune Therapy in Hematologic Malignancy Panel Discussion.mp4
- Clinical Considerations for Immune Checkpoint Toxicities Panel Discussion.mp4
- Clinical Updates in Head and Neck Squamous Cell Carcinoma.mp4
- Clinical Updates in Head and Neck Squamous Cell Carcinoma.pdf
- Clinical Updates in Lymphoma.mp4
- Clinical Updates in Lymphoma.pdf
- Clinical Updates in Metastatic Breast Cancer.mp4
- Clinical Updates in Metastatic Breast Cancer.pdf
- Clinical Updates in Myeloma.mp4
- Clinical Updates in Myeloma.pdf
- Clinical Updates in Rectal Squamous Cell Carcinoma.mp4
- Clinical Updates in Rectal Squamous Cell Carcinoma.pdf
- Clinical Updates in Sarcoma and Merkel Cell Carcinoma.mp4
- Clinical Updates in Sarcoma and Merkel Cell Carcinoma.pdf
- Clnical Updates in Non-Small Cell Lung Cancer.mp4
- Clnical Updates in Non-Small Cell Lung Cancer.pdf
- Cytokine Release Syndrome.mp4
- Cytokine Release Syndrome.pdf
- Discussion of Novel Checkpoint Inhibitors and Combination Therapy.mp4
- Discussion of Novel Checkpoint Inhibitors and Combination Therapy.pdf
- Fundamentals of Immune Checkpoint Blockade Panel Discussion.mp4
- Fundamentals of T Cell Therapy Panel Discussion.mp4
- Gastrointestinal Immune-Related Adverse Event- Colitis.mp4
- Gastrointestinal Immune-Related Adverse Event- Colitis.pdf
- Mechanism of Action and Clinical Applications of Tumor Infiltrating Lymphocytic (TIL) Therapy.mp4
- Mechanism of Action and Clinical Applications of Tumor Infiltrating Lymphocytic (TIL) Therapy.pdf
- Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4.mp4
- Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4.pdf
- Neurological Immune-Related Adverse Event- Myasthenia Gravis.mp4
- Neurological Immune-Related Adverse Event- Myasthenia Gravis.pdf
- Overview of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy.mp4
- Overview of Chimeric Antigen Receptor (CAR) T Cell Immunotherapy.pdf